Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Passes Below 200-Day Moving Average – Here’s Why

Shares of Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.37 and traded as low as $0.2844. Elite Pharmaceuticals shares last traded at $0.2950, with a volume of 900,854 shares traded.

Elite Pharmaceuticals Stock Down 0.8%

The firm’s fifty day simple moving average is $0.36 and its two-hundred day simple moving average is $0.37. The company has a current ratio of 3.76, a quick ratio of 2.97 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $317.76 million, a price-to-earnings ratio of 7.38 and a beta of 0.40.

Elite Pharmaceuticals (OTCMKTS:ELTP) last announced its quarterly earnings results on Thursday, August 13th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter. Elite Pharmaceuticals had a net margin of 40.19% and a return on equity of 44.58%.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.